<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716090</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-DLP-03(01/13)</org_study_id>
    <nct_id>NCT02716090</nct_id>
  </id_info>
  <brief_title>Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris</brief_title>
  <acronym>Narciso</acronym>
  <official_title>National Clinical Trial, Phase III, Monocentric, Randomized, Open, Controlled, Parallel Study to Assess the Non-inferiority of Dalap Duo® Product (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel Cream) Compared to Epiduo® (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel) in the Treatment of Acne Vulgaris in Population of Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the non-inferiority of the product Dalap Duo® compared to Epiduo®&#xD;
      medicine to treat acne. Half of the participants will receive Dalap Duo®, while the other&#xD;
      half will receive Epiduo®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational product produced by Aché that will be evaluated in this trial is a cream&#xD;
      gel, comprising 0.1% of adapalene 2.5% and benzoyl peroxide. It's a topical cream gel that is&#xD;
      stored on a laminated tube containing 30 grams.&#xD;
&#xD;
      Of the 376 research participants with acne vulgaris participating in the study, 188 will be&#xD;
      treated with the investigational product Cream Gel.&#xD;
&#xD;
      The duration of the participants in the study will be up to one hundred twenty-four days,&#xD;
      contemplating screening visit, randomization visit, four follow-up visits, a final visit and&#xD;
      a phone contact 30 days after final visit. Of the one hundred twenty and fourth days of the&#xD;
      study period, the participants will be treated for eighty four days.&#xD;
&#xD;
      Regarding the control group, the active comparator is Epiduo®, manufactured by Galderma&#xD;
      Laboratories, and its formulation is composed of 0.1% adapalene 2.5% and benzoyl peroxide.&#xD;
      This is a topical gel stored in laminated tube with 30 grams.&#xD;
&#xD;
      Of the 376 research participants with acne vulgaris that will participate in the study, 188&#xD;
      will be treated with the active comparator Epiduo®.&#xD;
&#xD;
      The duration of the participants in the study will be up to one hundred twenty-four days,&#xD;
      contemplating screening visit, randomization visit, four follow-up visits, a final visit and&#xD;
      a phone contact 30 days after final visit. Of One hundred twenty and fourth days of the study&#xD;
      period, the participants will be treated for eighty four days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to budget limitations, the company decided to withdraw this study.&#xD;
  </why_stopped>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of total acne lesion</measure>
    <time_frame>84 days</time_frame>
    <description>Percentage reduction of total acne lesion on the face other than the region of the nose by manual counting performed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of number of inflammatory lesions</measure>
    <time_frame>07, 14, 28, 56 and 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in non-inflammatory lesions</measure>
    <time_frame>07, 14, 28, 56 and 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of acne through Global assessment of investigator</measure>
    <time_frame>07, 14, 28, 56 and 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency perceived by participant</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Dalap Duo®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl peroxide Dalap Duo®</intervention_name>
    <arm_group_label>Dalap Duo®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl peroxide Epiduo®</intervention_name>
    <arm_group_label>Epiduo®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. female or male Participant&#xD;
&#xD;
          2. Age older than or equal to 12 years;&#xD;
&#xD;
          3. 30-100 non-inflammatory facial lesions, except in the nose region (comedo closed and&#xD;
             open comedo - degree 1) and 20 to 50 inflammatory facial lesions, except in the nose&#xD;
             region (papule and pustule - degree 2);&#xD;
&#xD;
          4. Ability to understand and consent to participate in this clinical study, expressed by&#xD;
             signing the consent form;&#xD;
&#xD;
          5. Search Participant willing to not use, for the entire period of the study drugs,&#xD;
             cosmetics and / or treatments for acne, according to the investigator, that may&#xD;
             influence the study results, such as, but not limited to, treatment with oral and&#xD;
             topical retinoids.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding of clinical observation (clinical assessment / physical) that is&#xD;
             interpreted by the investigator as a risk to safety or which may interfere with the&#xD;
             effectiveness of the treatment and research of the participants in the clinical trial;&#xD;
&#xD;
          2. Any laboratory examination found that the investigator consider as safety risk or that&#xD;
             may interfere with the effectiveness of the treatment and research of the participants&#xD;
             in the clinical trial;&#xD;
&#xD;
          3. Known hypersensitivity to the drug components used during the study;&#xD;
&#xD;
          4. female participants with a history of polycystic ovary syndrome (Stein-Leventhal&#xD;
             syndrome);&#xD;
&#xD;
          5. Women with positive result for urinary beta human chorionic gonadotropin or gestation&#xD;
             period or breastfeeding;&#xD;
&#xD;
          6. Women in the reproductive age who do not agree to use acceptable contraception [oral&#xD;
             contraceptives, injectable contraceptives, intrauterine device (IUD), hormonal&#xD;
             implants, barrier methods, hormonal patch and tubal ligation]; other than surgically&#xD;
             sterile (bilateral oophorectomy or hysterectomy) or sexual abstinence or who have not&#xD;
             yet initiated sexual activity;&#xD;
&#xD;
          7. Person who has participated in clinical trial protocols in the last twelve (12)&#xD;
             months, unless the investigator considers that there may be direct benefit to him/her;&#xD;
&#xD;
          8. Participant who has some kinship to the second degree or bond with employees or&#xD;
             employees of Sponsor and Research Center;&#xD;
&#xD;
          9. Women in menopausal or postmenopausal period;&#xD;
&#xD;
         10. Any feature in the test areas (face) that according to the investigator may influence&#xD;
             the results, for example, BUT NOT LIMITED TO moles, tattoos, scars, irritated skin,&#xD;
             scratches, cuts and excess hair;&#xD;
&#xD;
         11. Participants diagnosed with Diabetes Mellitus after evaluation of the result of the&#xD;
             test, defined as the presence of the classic symptoms of diabetes mellitus assessed&#xD;
             the visit V-1 associated with the higher level of casual plasma glucose or equal to&#xD;
             200 mg / dL according to the American Diabetes Association (DIABETES CARE, VOLUME 33,&#xD;
             SUPPLEMENT 1, JANUARY 2010);&#xD;
&#xD;
         12. Presence of dermatoses related to diabetes mellitus (plantar ulcer, necrobiosis&#xD;
             lipoid, annular granuloma, dermatophytosis, deep mycoses, bacterial infections,&#xD;
             opportunistic infections);&#xD;
&#xD;
         13. immune impairment;&#xD;
&#xD;
         14. Dermatological diseases in the test area (face): vitiligo, psoriasis, atopic&#xD;
             dermatitis;&#xD;
&#xD;
         15. Participant using topical treatment for acne in the 15 days preceding the screening&#xD;
             visit (V-1) or oral treatment for acne in the 30 days preceding the screening visit&#xD;
             (V-1) or plan to use during the study period;&#xD;
&#xD;
         16. Participant with cyst or lump in the face region;&#xD;
&#xD;
         17. Use of medication and / or treatment contrary as described in item 11.2. of the&#xD;
             Protocol;&#xD;
&#xD;
         18. Other diseases or medications, according to the investigator, that would interfere&#xD;
             directly in the results of the study or jeopardize the health of the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

